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Letters
Outcomes for Indigenous 
and non-Indigenous 
patients who access 
treatment for hepatitis C 
in the Top End of the 
Northern Territory
TO THE EDITOR: Chronic hepatitis C 
virus (HCV) infection affects over 
225000 Australians1 and is a leading 
cause of the need for liver 
transplantation and of liver-related 
death, but curative treatments are 
available. Ethnicity is a major 
determinant of treatment 
responsiveness, with the lowest 
sustained virological response (SVR) 
rates reported in African patients, and 
the highest in Asian p tients.2 Much of 
this difference is accounted for by racial 
differences in polymorphisms in the 
interleukin-28B (IL28B) gene;3 
however, it is unknown how common 
these polymorphisms are in Indigenous 
Australians, and no studies have been 
published about hepatitis C treatment 
outcomes among Indigenous 
Australians.
The hepatitis C treatment service for 
the Top End of the Northern Territory 
is run from a community-based sexual 
health clinic in Darwin. As clinicians 
working at this service, our perception 
was that Indigenous people rarely 
accessed the service or received 
treatment for HCV infection. Further, 
we were concerned that — due to 
social, cultural and linguistic barriers 
— Indigenous people who accessed 
the service may be less likely to 
commence treatment and to 
successfully complete treatment and 
achieve an SVR. Following ethics 
approval from the Human Research 
Ethics Committee of the Northern 
Territory Department of Health and 
Families, we performed a retrospective 
case-note audit to determine the 
number of Indigenous people 
accessing the hepatitis C treatment 
service and their characteristics and 
treatment outcomes.
During the period 1 January 2006 to 
31 December 2010, 243 patients were 
seen on at least two occasions for 
assessment of HCV infection; all were 
adults and 22 (9%) were Indigenous. 
During the audit period, HCV infection 
was treated with pegylated interferon- 
plus ribavirin for 24–48 weeks. There 
were no significant differences in the 
proportion of patients who went on to 
commence and complete treatment, 
and to achieve an SVR, between 
Indigenous and non-Indigenous 
patients (Box). Of five Indigenous 
patients tested for IL28B genotype, all 
had the favourable CC polymorphism 
at the rs12979860 locus. Compared with 
the unfavourable TT and CT 
polymorphisms, the CC polymorphism 
at this locus is associated with at least a 
twofold higher chance of achieving a 
cure of HCV with interferon treatment, 
due to enhanced host immune 
responsiveness to interferon.3
In conclusion, Indigenous people in 
the NT who access hepatitis C 
treatment services have a similar chance 
of achieving a cure (SVR) to non-
Indigenous people. This may be partly 
because they are likely to carry the 
favourable CC polymorphism at the 
IL28B gene.
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“Indigenous 
people in the NT 
who access 
hepatitis C 
treatment 
services have a 
similar chance 
of achieving 
a cure . . . to 
non-Indigenous 
people
” Davis et al
Indigenous compared with non-Indigenous patients who attended a hepatitis C treatment service on at 
least two occasions for assessment of HCV infection*
Indigenous (n = 22) Non-Indigenous (n = 221) P
Age, median (interquartile range) 41.0 (36.2–45.0) 47.3 (39.3–52.1) 0.14
Men 15/22 (68% [45%–86%]) 144/221 (65% [58%–71%]) 0.78
HCV genotype 1 10/18 (56% [31%–78%]) 87/173 (50% [43%–58%]) 0.67
Commenced HCV treatment 11/22 (50% [28%–72%]) 99/221 (45% [38%–52%]) 0.58
Completed HCV treatment 9/11 (82% [48%–98%]) 80/99 (81% [72%–88%]) 0.94
Achieved sustained virological response† 4/8 (50% [16%–84%]) 54/88 (61% [50%–72%]) 0.53
HCV = hepatitis C virus. * Data are number/denominator (% [95% CI]) unless otherwise indicated. † Denominators represent 
those patients for whom 6-month post-treatment blood test results were available. ◆
